Methyl (S)-3-(4-bromothiazol-2-yl)-2-((tert-butoxycarbonyl)amino)propanoate serves as an advanced non-natural chiral amino acid derivative and pharmaceutical intermediate. It is primarily utilized in building the structural frameworks of novel small-molecule targeted therapeutics, anti-cancer agents, antivirals, and bioactive peptidomimetics. The highly reactive bromothiazole ring in its molecule facilitates diverse functionalization via Suzuki, Stille, or Buchwald coupling reactions. Meanwhile, its defined chiral center guarantees stereospecific synthesis for peptide-based drug discovery, making it a vital chemical building block for pharmaceutical R&D and commercial lead optimization.

RMC-6236 intermediate; Daraxonrasib intermediate